Intervention 1: Intervention group: receiving 80 micrograms of RBD protein recombinant SARS-CoV-2 vaccine in days 0, 21, and 35

2 trials

Sponsors

Bagheiat-allah University of Medical Sciences

Conditions

COVID-19. COVID-19, virus identifiedCOVID-19. U07.1 COVID-19, virus identified

Phase 1

Safety and immunogenicity of COVID-19 RBD protein recombinant vaccine (AmitisGen): phase I study.

RecruitingIRCT20210620051639N1

Bagheiat-allah University of Medical SciencesCOVID-19. COVID-19, virus identified

Start: 2021-06-25Target: 70Updated: 2021-07-12

Phase 2

Clinical trial of Noora vaccine

RecruitingIRCT20210620051639N2

Bagheiat-allah University of Medical SciencesCOVID-19. U07.1 COVID-19, virus identified

Start: 2021-10-12Target: 300Updated: 2021-11-01